Annals of Cancer Research and Therapy
Online ISSN : 1880-5469
Print ISSN : 1344-6835
ISSN-L : 1344-6835
TREATMENT OF GASTRIC CANCER FOR SURVIVAL-STRATEGIES IN THE USA AND JAPAN
Lisa Baddi, Mary Mulcahy, Al Benson III
Author information
Keywords: Adenocarcinoma, bryostatin, cis-platin, docetaxel, drug toxicity, 5-FU, G17DT, gastric cancer, irinotecan, LV5FU2, marimastat, phase II and III trials, survival, V325
JOURNAL FREE ACCESS

2003 Volume 11 Issue 1-2 Pages 15-30

Details
Download PDF (683K)
Download citation RIS

(compatible with EndNote, Reference Manager, ProCite, RefWorks)

BIB TEX

(compatible with BibDesk, LaTeX)

Text
How to download citation
Contact us
Abstract
Chemotherapy has been shown to benefit patients with gastric cancer. The most effective regimen remains controversial. A recent large randomized clinical trial has demonstrated an advantage with the addition of docetaxel to 5-fluorouracil and cisplatin. New agents are being incorporated into the treatment of gastric cancer to maximize efficacy with minimal additional toxicity. Future clinical trials will explore the use of new agents as well as genetic polymorphisms that may influence drug metabolism and efficacy.
Content from these authors
© by The Japanese Society of Strategies for Cancer Research and Therapy
Previous article Next article
Favorites & Alerts

Recently viewed articles
Share this page
feedback
 Top